The most compelling HNSCC-specific evidence derives from the phase II TROPiCS-03 trial (NCT03964727), which enrolled 43 heavily pretreated patients who had progressed after platinum chemotherapy and anti–PD-(L)1 therapy [141]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.